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Control of African animal trypanosomia-
sis (AAT) is hampered by limited diag-
nostics, inappropriate trypanocide use,
poor drug quality, and drug resistance.
The scope and quality of current litera-
ture on AAT incidence, control, and
resistance does not allow for robust
comparisons or assessment of the valid-
ity of extrapolating to other populations.
A united effort is needed to addressTrypanocides are a key control component of African animal trypanosomiasis
(AAT) in tsetse-infested areas of sub-Saharan Africa.While farmers are dependent
upon trypanocides, recent research highlights their inappropriate and ineffective
use, problems with drug quality, and treatment failure. There are currently gaps
in knowledge and investment in inexpensive AAT diagnostics, understanding of
drug resistance, and the effective use of trypanocides in the field. Without this
important knowledge it is difficult to develop best practice and policy for existing
drugs or to inform development and use of new drugs. There needs to be better
understanding of the drivers and behavioural practices around trypanocide
use so that they can be incorporated into sustainable solutions needed for the
development of effective control of AAT.AAT at local, national, and international
settings to ensure a greater chance for
success.
AAT control programmes must be sus-
tainable through funding, cross-sectoral
engagement, and fostering sustainable
behavioural change through incentives
and accountability.
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(S. Richards).Obstacles to improving trypanocide use in AAT
African animal trypanosomiasis (AAT) (see Glossary) is an important constraint on livestock
production in parts of sub-Saharan Africa (SSA) where the tsetse fly vector is found. Improving
AAT control is important for development and food security, whilst potential impacts on the risk
of human African trypanosomiasis (HAT) highlight its value as a One Health intervention [1–3].
Trypanocides (Box 1) are a key control component of AAT. Whilst a recent review [4] described
antitrypanosomal chemotherapy, there is an urgent need to consider our understanding of how
these widely available drugs are used in the field. This is needed to improve effective use of
existing drugs; it is timely because these issues are relevant to the implementation of new
trypanocides that are under development. This paper reviews recent literature on trypanocide
usage, effectiveness, and resistance, and identifies barriers to optimal use in order to make
recommendations regarding future trypanocide use.
The role of trypanocides in AAT control
The direct and indirect control options for AAT are summarized by Meyer et al. [5] in their system-
atic review. Trypanocides are used for the prevention and treatment of infection in individual or
groups of cattle, whilst tsetse control includes the aerial- or ground-based application of insecti-
cide to the resting sites of tsetse, or baits (targets or insecticide-treated cattle) to attract and
kill tsetse (Figure 1). Despite significant investment in tsetse control, in 2001 it was estimated that
vector-control operations covered only <2% of tsetse-infested areas [6].
However, livestock keepers often adopt vector-control methods. For instance, in parts of
Tanzania [2], Zimbabwe [7], and Uganda [8,9], there is widespread treatment of cattle with pyre-
throids to control ticks and tsetse. Whilst livestock keepers usually treat their animals to protect
their own herd, insecticide treatment of cattle is proven in its ability to reduce tsetse populationsTrends in Parasitology, Month 2021, Vol. xx, No. xx https://doi.org/10.1016/j.pt.2021.04.007 1
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Box 1. Trypanocides used to treat and prevent AAT in ruminants
There are three trypanocides available for use in sub-Saharan Africa for AAT in ruminants: diminazene aceturate (DZ),
isometamidium chloride (ISM), and homidium salts (HM – also known as ethidium bromide). While a range of doses is
described in the literature for these medications, on the packaging for retail sale there is typically only one dose listed.
DZ was introduced in 1955 for use in livestock and is used as a curative therapy. It is administered by intramuscular (IM) or
subcutaneous (SC) route at a dose of 3–5 mg/kg [4]. DZ is usually sold in single-dose sachets of powder that must be
diluted with sterile water.
ISMwas introduced in the 1960s and is given via deep IM injection for treatment or prophylaxis at 0.25–1mg/kg [4]. It is the
only drug labelled for prophylaxis of AAT. Administration is associated with lesions at the site of IM injection, especially with
long-term use. If used IV, the prophylactic effects are negated, whereas with IM administration it results in a 2–6 month
prophylactic period. ISM is sold in a multi- or single-dose sachet of powder that must be diluted with sterile water.
HM was introduced in 1952 and is given by deep IM in cattle or IV in small ruminants at 1 mg/kg for treatment [4]. It is
known for its proven mutagenic and possible carcinogenic risk and its use is discouraged [4]. HM does have some
prophylactic properties but less so than ISM. HM is sold in a tablet form that must be ground and diluted with sterile water.
Quinapyramine was used in cattle between 1950 and 1970 but was removed from the market due to toxicity and resis-





(AAT): a disease of domestic animals
caused by parasitic protozoa of the
genus Trypanosoma across sub-
Saharan Africa. Cattle, sheep, and goats
are infected by strains of T. congolense,
T. vivax, and T. brucei. Human African
trypanosomiasis (HAT) is a disease of
humans, caused by T. brucei
rhodesiense and T. brucei gambiense,
and it is zoonotic. AAT and HAT are
transmitted by the tsetse fly (Glossina
spp.) vector, and T. vivax can also be
transmitted by biting flies.
Trypanosomes have highly variable
surface antigens that regularly change,
making antibody responses ineffective,
leading to persistent infections, and
preventing the development of vaccines.
Clinical signs in ruminants include
anaemia, poor body condition,
intermittent fever, poor appetite, dull/
staring coat (rough and upstanding
appearance to hair), lymph node
enlargement, abortion, reduced milk
yield, diarrhoea, dehydration, and
increased lachrymation. Cattle typically
have chronic infections, which can
include high mortality, especially if
already in poor condition or stressed.
Antimicrobial resistance (AMR) or
resistance: the characteristic of those
parasites, bacteria, viruses, or fungi
which no longer respond to medications
(like trypanocides) used to manageand hence reduce the incidence of AAT [10] if applied to enough cattle at relatively large scale and
with even coverage [11]. For example, one model evaluating the control of AAT with insecticides
found that a minimum of 20% of cattle must be treated over a relatively large area (>100 km2) for
effective control, whereas individual animals may be treated with trypanocides to protect or cure
them [11]. Similarly, Shaw et al. [12] evaluated the cost benefit of control methods and found that
only when there is sufficient cattle density (>10 cattle/km2) is insecticide use profitable.
Despite insecticide use, most livestock keepers regard trypanocides as the primary option for AAT
control. In Tanzania, it is reported that 0–45% of farmers, depending on district, were aware that
tsetse control could control AAT, whilst up to 60% of farmers reported using chemotherapy as a
control method for AAT [13]. In several countries, for example, Togo [14], AAT control is almostPredominantly farmer-led




















Figure 1. Control options for African animal trypanosomiasis (AAT) highlighting farmer versus community or
centrally required coordination. Adapted from [5]. Control measures for AAT are highlighted, with predominantly
farmer-led methods indicated by the upper arrow, where items to the left of the figure are more easily implemented and
utilized by individual farmers. Predominantly centrally or community-led control measures are indicated by the lower arrow
where items to the right of the figure are more easily and effectively implemented by central bodies such as governmen
agencies or communities.
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associated infections, due to an intrinsic
change in which the pathogen lowers its
sensitivity to a drug. This is one way in
which treatment failure occurs.
Insecticide-treated cattle: cattle
which have been treated with synthetic
pyrethroids, such as alphacypermethrin
and deltamethrin, that are applied by
spraying, dipping, or pour-on methods;
these agents can kill tsetse flies.
Spraying and dipping require more
infrastructure or equipment than the
pour-on approach. The frequency of
application depends on how long the
insecticide remains active on animals. In
field settings, insecticides are applied as
often as weekly.
One Health: the interaction between
animal, human, and environmental
health as it pertains to collaborative
approaches to improving cross-sectoral
health outcomes.
Progressive control pathway (PCP):
a five-stage stepwise approach to
reduce, eliminate, and eradicate a,
t disease. Stages include preparatory
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work prior to entering the PCP with
political and financial commitments
nationally: stage 1 for capacity
development and disease-risk mapping,
stage 2 for reduction of AAT, stage 3 to
eliminate AAT transmission, stage 4
when AAT is eliminated but control
measures remain, stage 5 when AAT is
eliminated and control measures are no
longer practiced.
Prophylactic: any medication used to
prevent a disease from occurring.
Targets: insecticide-treated panels of
cloth, sometimes baited with artificial
attractants, used to attract and kill tsetse
flies.
Treatment failure: the situation that
occurs when a treatment is applied to an
infectious disease and the symptoms of
the disease do not resolve and/or test
results show continued infection.
Trypanotolerant cattle breeds:
certain breeds of African taurine cattle
that are intrinsically at a reduced risk of
developing clinical symptoms with AAT
as compared to trypanosusceptible
breeds (indicine and European taurine
breeds exotic to Africa).
Veterinary services: animal healthcare
provided by trained professionals,
inclusive of veterinarians, paravets,
animal health technicians, and
community animal health workers.exclusively based on chemotherapy, without insecticide use or other tsetse-control approaches. It
is clear that trypanocides will remain a fundamental part of AAT control.
Quantifying trypanocide use in the field
The trypanocide (Box 1) market comprises both formal and informal sectors; HealthforAnimals,
formerly the International Federation for Animal Health, estimates that the trade of unregistered
and substandard veterinary drugs in Africa is valued at US$400 million annually, which is esti-
mated to be of similar value to the official marketi. The use of trypanocides is hard to enumerate
and robust published data are rare. Estimates of annual usage of trypanocides range in SSA
from 35 million doses to 50 million doses [15–17] with a total value of US$20 million [18] to US
$90 million [19,20]. Notably, although these estimates are very widely cited, none of these refer-
ences provide methodology, making it impossible to assess their robustness or to consider likely
trends over time. Country-level estimates of the trypanocide market are rare, but US$8.4 million
was spent on trypanocides annually in southwest Nigeria, representing the largest class of pur-
chased cattle drugs [21,22]. A more accurate method to determine trypanocide use would be
to evaluate records of import of veterinary drug suppliers, as was done in Cameroon for antibi-
otics in livestock; however, there are no similar reports in the literature on trypanocides [23].
Individual dose costs for trypanocides in Nigeria have been estimated at US$2–3.55, whilst
across SSA the cost of single doses of drug are estimated to fall between US$0.50 and
US$3.00 [19]. In Uganda, the cost of a single dose of both diminazene aceturate (DZ) with
added vitamin B12, and isometamidium chloride (ISM) for a 192 kg cow was US$0.64 and
US$1.00 respectively, and US$1.42 and US$1.78 inclusive of required supplies and delivery
of injection respectively [24]. Holt et al. [25] surveyed livestock owners across five SSA
countries to identify the costs of trypanocides used and reported that 16–63% of livestock
owners spent more than US$55/2 years, depending on location, herd size, and cattle breed
(trypanotolerant vs. susceptible).
The evident data gaps on trypanocide use are consistent with arguments made by Grace [26] in
evaluating antimicrobial resistance (AMR), likely reflecting the limitations of low- to middle-
income countries (LMICs) in surveillance capabilities for antimicrobial use [27]. Lack of reliable
data on frequency and quantities of trypanocide use in AAT make it difficult to quantify the
potential impact of issues such as treatment failure or resistance.
Effectiveness of trypanocides for treatment and prophylaxis of AAT in the field
Farmer practices in the use of trypanocides for AAT
Across SSA, most reports indicate that over 50% (range 1–90%) of farmers treat their own live-
stock with drugs when needed [22,28–33]. Farmers use nonspecific indicators such as body
condition scoring and visual assessment to make treatment decisions [30,31] and they often
do not focus on disease aetiologies [29]. Additionally, a challenge with diagnosing AAT in settings
where the circulation of multiple infectious diseases [34,35] is the norm, is that many clinical signs
associated with the disease are not specific to AAT [34]. In the absence of veterinary services
or available diagnostics, it is therefore not surprising that farmers regularly misdiagnose livestock
disease [30]. In one study in Kenya, it was estimated that a third of all drug treatments given to
livestock were trypanocides, but 53.5% of treatments for trypanosomiasis were administered
inappropriately to cattle that likely did not have AAT [36].
Farmer decision-making on type and frequency of trypanocide administration is complicated and
nuanced. Clinical signs shown by the animal, farmer preferences, costs of medications, and
success of their first used treatment all play a major role in choices of trypanocides [21,32]. InTrends in Parasitology, Month 2021, Vol. xx, No. xx 3
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antibiotics [37] at the same time. Choice and frequency of trypanocides can also be influenced
by the age class and working requirements of animals [38].
Farmers in Nigeria, Ethiopia, and across a multisite study in SSA reported that DZ was their
first-choice treatment for AAT on 55–79% of occasions, whereas only 8–21% chose ISM as
their first-line treatment [22,28,32,38]. Farmers use DZ to treat individual sick cattle, or whole
herds, and in some cases, they indicate using it as a prophylactic, even though this medication
has no prophylactic capability [13,31,38]. ISM, by contrast, is a prophylactic and is used as such
but quite variably, with usage reported less frequently in Tanzania and Ethiopia (5–45% use ISM)
[13,38], than in Zambia (99% use ISM) where ISM is reportedly used by farmers upwards of four
times/year [31]. In Nigeria, across all trypanocide and treatment options for AAT, most are given
twice seasonally [22], and in Ethiopia individual cattle are treated upwards of seven times/year
[32]. Several authors conclude that farmers prefer DZ as it is less costly, single dose, and also
treats Babesia infections, and it is the farmers' preference for treating AAT cases (DZ is for treat-
ment) as opposed to using prophylaxis [13,32,38]; however, more robust studies of the factors
driving trypanocide use are needed. No recent published data on the use of homidium salts
(HM) are available, although anecdotally HM is still widely used in some areas.
Farmer-reported use has demonstrated issues with both underdosing and overdosing of
trypanocides, as well as with other antimicrobials more generally [21,28,30,31]. For example,
farmers in southwestern Ethiopia base trypanocide dose on age class of animal, but generally
overdosed young animals (87% of DZ doses in young animals were overdoses) and underdosed
adults (40% of ISM doses in adults were underdoses) [38]. Interestingly, DZ was dosed correctly
94% of the time in adult cattle, as compared with 40% in the case of ISM treatment [38]. This
could be due to the higher cost of ISM, or because it is sold in a multidose sachet in some
localities as opposed to DZ, which is usually sold as a single-dose sachet. In Nigeria, inappropriate
dosing was due to farmers tending not to review the concentration of the trypanocide, the dose, or
the animal's weight in their decision-making process [22]. The use of expired or improperly stored
medication can also lead to treatment failure [13,29,39], and in Ethiopia, 56.7% of farmers did not
check expiry date [39]. Language barriers and literacy can also impede reading of the expiry date
and dosing recommendations on packages of medications, with instructions rarely provided in
local languages.
In order to achieve optimal therapeutic range, trypanocides currently on the market are licensed
to be administered by deep intramuscular (IM) injection (Box 1); however, only 68–74% of farmers
correctly identified the route by which to administer medication in one study in Mali and Burkina
Faso [28]. In Tanzania, up to 75% of farmers preferred the intravenous (IV) route of administration
for trypanocides because they believed it to be faster-acting, whereas others opted for both IM
and IV administration concurrently. Inappropriate routes of administration can lead to treatment
and prophylaxis failure, and to injection-site reactions, which was noted in 24% of cases in
West Africa [30] (see also Box 1).
Lack of access to diagnostics when making decisions on treatment with trypanocides
Farmers base diagnosis of AAT on clinical symptoms as they do not usually have access to
diagnostic tools. Current diagnostics for AAT require costly equipment and skilled interpretation
(Box 2). Given limited laboratory capacity in LMICs, these facilities are often confined to regional
laboratories, constraining access of farmers and veterinary services [26]. There is limited evidence
assessing the success rate of farmers diagnosing AAT correctly based on clinical signs. One small
study in West Africa reported that, among farmer-diagnosed cattle, 84% had evidence of AAT on4 Trends in Parasitology, Month 2021, Vol. xx, No. xx
Box 2. Commonly used diagnostic methods for AAT
Parasitological diagnosis can be achieved by wet and Giemsa-stained blood films but this has low sensitivity, especially
when there are low levels of parasites in the blood, which is common in chronic infections. Trypanosomes in blood can
be concentrated by the haematocrit centrifugation technique (HCT) with subsequent examination of the buffy coat/plasma
junction. Sensitivity is further improved through evaluation with the buffy coat technique (BCT) in which the haematocrit
tube is cut and the buffy coat/plasma layer is applied to a slide for dark-ground or phase-contrast microscopy. These
methods increase sensitivity due to concentrating the parasites; however, a threshold of 2.5 × 102 parasites/ml of blood
is required to detect infection via these methods. These methods can be used in the field provided a microscope and
centrifuge are available.
Subinoculation of blood from suspected infectious animals can be injected into clean recipient hosts, such as immunosup-
pressed rodents. This method is costly, labour intensive, and requires expertise, but can be more sensitive depending on
the species of trypanosome (it typically fails with T. vivax as very few strains grow in mice).
Immunological diagnostic methods are more sensitive and can be done by complement fixation, indirect fluorescent
antibody test, card agglutination trypanosomiasis test, and ELISA (antigen and antibody). One serological test (VeryDIAG)
is commercially available as a rapid diagnostic test; it targets antibodies against different T. congolense and T. vivax
antigens [58]. All serological tests are relatively expensive, and all current tests are based upon antibody detection,
meaning that they cannot differentiate between active and recent infection and can require technical capabilities (VeryDIAG
being the only ‘pen-side’ test available). Molecular methods such as PCR can be used to gain species-specific diagnosis
but they are expensive and require sample processing, expertise, and equipment. Potentially field-friendly isothermal PCR
assays, such as LAMP, have been designed for the AAT species, but have not been developed to the point of field
deployment. Whilst further pen-side diagnostics are under development, reducing the costs sufficiently to make them
accessible to livestock keepers is challenging.
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correct for AAT based on the clinical symptoms described (but unconfirmed by laboratory testing)
[36]. However, these studies are too small to draw generalizable conclusions. Decision-support
tools have been proposed to assist vets and extension workers in differentiating endemic diseases
of cattle in SSA on the basis of clinical presentation [40], but to our knowledge have not yet been
validated against gold-standard diagnostics.
Drug quality and counterfeit drugs
Farmers across SSA have reported concerns about poor drug quality, stating that some brands
are more trustworthy than others and attributing treatment failure to drug quality up to 61% of the
time [21,25,29]. It is difficult for farmers to gauge drug quality, with purchasing drugs likened to a
lottery [21]. Farmers cannot easily assess the performance of a drug, since treatment success is
confounded by dose, method of administration, and whether the animal actually has AAT.
Farmers' concerns are legitimate with quality analysis of DZ and ISM in West Africa, Togo, and
Ethiopia, indicating that 51.9%, 40%, and 28% of drugs were noncompliant (i.e., not containing
the correct dose of active ingredient), respectively [32,41,42]. Compliance varied by country of
sale, country of manufacture and official vs non-official sources. ISM was found to have a higher
rate of noncompliance acrossWest Africa [42] as compared to DZ, but the opposite was found in
Togo [41], and no significant difference was found in Ethiopia [32]. The sample sizes in these
studies were small, limiting the conclusions that can be drawn and reflecting similar challenges
in relation to AMR and drug quality where anecdotal mentions in the literature exceed the few
systematic studies [43].
Poor-quality drugs can arise from both illegal (i.e., counterfeit) production and substandard
practices that are related to the difficulty in producing trypanocides under good manufacturing
practice quality standards [21]. Counterfeiting is hard to corroborate in the literature as it is illegal;
however, it is exacerbated by inadequate veterinary practice or state-enforced controls [21].
Substandard production issues are amplified by country-level regulators having limited capacityTrends in Parasitology, Month 2021, Vol. xx, No. xx 5
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have been published for DZ, ISM, and HM, there is no agreed international standard for quality
control, although work was started in 2014 to support this effort [19].
Resistance to DZ and ISM across SSA
Reports of treatment failure with trypanocides in SSA stretch back to at least 1991 [44]; however,
trypanocide resistance can be hard to differentiate from the other causes of treatment failure, and
the epidemiology and impact of trypanocide resistance remain unclear. Literature on resistance
suffers from variable methodology and robustness, inconsistent diagnostic tests and reporting,
small sample sizes, and is heavily focused on Trypanosoma congolense (Table 1). These issues
are similar to those for AMR research generally in LMICs [26]. Tests for resistance in cases of AAT
are limited to few options (Box 3) and involve evaluating response to treatment in animal models
[45]. No reliable genetic marker for resistance to veterinary trypanocides has been verified. There
are, accordingly, few publications on objectively evaluated resistance rates, and almost no
literature that distinguishes true resistance from simple reinfection or treatment failure for other
reasons. Although it is clear that treatment failure is common, and at least some failures are likely
to relate to true parasite resistance to drugs, definitive evidence is scant and improved methods
to detect and follow drug resistance are needed. Although it is often suggested that resistance is
increasing over time, the lack of robust data means that inference regarding trends, risk factors,
or impact of resistance is limited (Table 1 and Box 4).
Limited data on clinical cure rates and treatment failure
There aremultiple reasonswhy treatment failure can occur, including inappropriate administration
(i.e., the animal does not have AAT), incorrect dosage or route of administration, low drug quality,
and resistance. However, there is limited information on clinical cure rates or the relative impor-
tance of these factors. The only relevant data stem from results of drug-resistance studies
(Table 1) which often suffer from inconsistent approaches, and are rarely representative of how
trypanocides are used in a field setting, and farmer-reported success rates [25,28,32,38,39,46]
which are constrained by the lack of objective diagnostic tests (Boxes 2, 3). There is currently
no research that the authors could find to indicate the true rate of treatment failure or cure in a
field setting (farmer-treated livestock) on clinical cases of AAT diagnosed by laboratory methods.
Current influences on trypanocide use in the field
The frequency of trypanocide use varies greatly, with drivers affecting AAT exposure (such as
proximity to game management areas, intensive vs. extensive management, grazing practices,
seasonality), culture and beliefs (ethnic group, historical control procedures), and socioeconomic
status [21,25,29,31]. Most of these drivers also affect the likelihood that drugs are used appropriately,
through their influence on access to veterinary services. Across SSA, most pharmaceuticals
used in livestock are administered without veterinary oversight [13,26,29,30,32,38]. The
overarching reasons leading to inappropriate use of livestock medications include the high
number of animals requiring treatment, scarcity of veterinarians or animal-health professionals,
and lack of capacity to implement a veterinary system with appropriate oversight for prescription-
based medications [26].
Whilst, historically, responsibility for AAT control largely fell to government, with state-funded
tsetse-control programmes, following the transition from state to private veterinary services in
the 1980s, systems began to suffer from lower-quality products, unsubsidized services/inputs,
unregulated practices, and underserved communities – especially in rural areas [21]. The gap in
services has been filled by farmers purchasing medication at private pharmacies or open
markets, but the lack of capacity for providing animal-health services has limited oversight of6 Trends in Parasitology, Month 2021, Vol. xx, No. xx
Table 1. Recent reports of resistance to diminazene aceturate and isometamidium chloride across
sub-Saharan Africaa
Location and methods Reports of resistance Refs
Southwest Ethiopia
- Longitudinal study of n = 106 positive (cases) and
n = 119 negative (controls) cattle diagnosed by
Woo haematocrit centrifuge technique.
- Visited monthly for 6 months for Woo technique
testing
- Positive cattle at any visit or with PCV <18% were
treated with DZ, and if remained positive a double
dose of DZ, and if still positive a dose of ISM.
- T. congolense samples analysed using the invalid
DpnII-PCR-RFLP resistance test, hence no con-
clusions can be inferred from those test results
- Resistance to DZ
- Four outcomes following treatment evaluated
(i) new infections, (ii) relapse, (iii) combination of
both, (iv) cure
- Results: over 6-month monitoring of infected and
uninfected cattle, 40% of events were new
infections, 37.5% relapses, and 22.5% cure rate
- Lack of flow diagram to identify positive animals
over course of study
[38]
Zambezia province, Mozambique
- Intervention study with random allocation to either
ISM or DZ across three study sites
- Study site 1 n = 31 (DZ); n = 34 (ISM)
- Study site 2 n = 10 (DZ); n = 11 (ISM)
- Study site 3 n = 10 (DZ); n = 10 (ISM)
- Monitored day 0, 14, 28 post-treatment, then
interventions swapped between groups and
monitored for a further 14 days
- Outcome is blood test results by BCT and PCR
- Day 14 and 28 results indicative of drug resistance
- Day 42 results indicative of multidrug resistance
- Resistance to DZ and ISM
- Results: evaluation of cattle following treatment by
combined BCT and PCR test results
- Site 1 had 23% and 26% positive animals in the
DZ treatment group at days 14, 28
- Site 1 had 14% and 14% positive animals in the
ISM treatment groups at days 14, 28
- Site 2 had 50% positive animals in the DZ
treatment groups at days 14 and 28
- Site 2 had 36% and 18% positive animals in the
ISM treatment groups at days 14, 28
- At day 42, site 1, 12% animals tested positive,
and at site 2 a total of 19% animals tested
positive
- Site 3 had no reports of positive cases following
treatment
- Unclear if positive animals at each stage were




- One herd (n = 79) of cattle in Nigeria where 54.4%
(n = 43) of cattle were positive based on micros-
copy for AAT were treated with DZ and tested by
ITS-PCR 2 months post-treatment
- Resistance to DZ
- Results: evaluation of cattle herd following
treatment
- 19/79 cattle were positive 2 months following
treatment
- Unclear if 19 parasite-positive cattle were cattle
parasite-positive at day 0 and 2 months
post-treatment (reinfection vs. resistance unclear)
[64]
Northern Togo
- Intervention study with two groups of positive cattle;
one treated with DZ (n = 50) and other with ISM
(n = 50)
- monitored by PCV and BCT at day 14 and 28
post-treatment
- DpnII-PCR-RFLP DZ resistance testing of
positive T. congolense samples from the
intervention study and an earlier cross-sectional
study using the invalid DpnII-PCR-RFLP
resistance test, hence no conclusions can be
inferred from these results
- Resistance to DZ and ISM
- Results: in the DZ-treated animals, there was a
14% failure rate on day 14 overall
- In the ISM-treated animals, there was a
cumulative failure rate (days 14 and 28) of 26%
- Unclear if positive animals at each stage of testing
were the same animals or new animals testing
positive (reinfection vs. resistance unclear)
[14]
Southeast Mali
- Intervention study with two groups of positive
cattle; one treated with DZ (n = 62) and the other
with ISM (n = 63)
- Monitored at days 14 (DZ and ISM) and 28 (ISM)
for PCV and trypanosomes by dark-ground phase-
contrast microscopy
- Resistance to DZ and ISM
- Results: at day 14, (32%) of cattle were still
positive following treatment with ISM
- Of the 43 cattle that were negative at day 14
in the ISM group, 11 (26%) were positive at
day 28
- T. congolense accounted for 77% of all ISM
treatment failures
[65]
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Table 1. (continued)
Location and methods Reports of resistance Refs
- At day 14 following treatment in the DZ group,
31% remained positive and retreatment with a
double dose of DZ still led to treatment failure
in 26% of cases
- T. congolense accounted for all of the DZ
treatment failures
Northwest Ethiopia
- Intervention study where purchased cattle (n = 24)
were divided into four equal groups; half were
exposed to T. vivax from tsetse-infested areas,
and half with T. vivax from non-tsetse areas
- Exposure was via intravenous inoculation
- Then within each exposed group either ISM or DZ
was given (2 DZ groups and 2 ISM groups) at
peak parasitaemia
- Cattle evaluated by physical exam, PCV, the
Murray method of microscopy (BCT) twice a week
for 100 days
- If relapse of infection occurred the treatment with
a different drug than first used was initiated
- Treatment considered successful if negative
following treatment with one or two doses of
trypanocides given
- Relapse considered if trypanosomes detected
following trypanocidal drug administration
- Resistance of T. vivax to DZ and ISM
- Results: following drug administration in all cattle,
parasitaemia significantly reduced within 24 h
- 9 (37.5%) cattle showed relapsing infections, 4
from the non-tsetse-infested T. vivax, 2 from ISM
and 2 from DZ; and 5 from the tsetse-infested
T. vivax, 3 from ISM, and 2 from DZ
- relapses began 35 and 56 days post-treatment
across all 9 animals
[66]
aAbbreviations: BCT, buffy coat technique; DpnII-PCR-RFLP, diagnostic test aimed to evaluate for resistance gene for DZ,
but subsequently shown to be spurious since the gene evaluated (TcoAT1) is not involved with drug resistance; DZ,
diminazene aceturate; ISM, isometamidium chloride; PCR, polymerase chain reaction; PCV, packed cell volume.
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advice. The limited services that are available in many areas are not always utilized by farmers
for reasons of mistrust, preference for local traditional medicines, cost, or a perceived lack of
benefit if they believe that they can do the same job themselves [13,47,48]. In one study in
Tanzania, 82.3% of farmers reported that they did not request veterinary services but instead
used medication or local remedies themselves [13]. The trends in Tanzania show that, in more
densely populated urban areas with smaller intensive/mixed farming used for market sales,
having a greater knowledge of AAT, and being in a high-burden area, led to the greater use of
veterinary services [29]. But across five SSA countries where there are large, extensively
managed trypanosusceptible cattle herds in high-risk areas, and where farmers were more likely to
self-diagnose and treat their cattle, the farmers were less likely to consult animal-health professionals
[25]. In the absence of other animal-health services, farmers commonly rely on trial-and-error
methodology, and seeking advice from friends, family, neighbours, and small-scale retailers with
whom they have built trusted relationships [13,21,29,33,49].
This scenario has led to a proliferation of drug manufacturers and distributors, as well as informal
markets, through which farmers directly purchase drugs in the absence of veterinary oversight
[13,21,31,32]. In Ethiopia, two studies found that 56% and 33.9% of farmers obtained their
medication from the unauthorized market or illegal drug market, respectively [32,47]. More
specifically to trypanocides, one Ethiopian study reported that 97.5% of farmers obtain these drugs
from informal pharmacies [39] which offer limited education or services to farmers [50]. The education
level of the staff in veterinary pharmacies and drug shops or agrovets is variable, with only 56%having
attained higher education degrees, and the condition of the shops in relation to drug storage and
handling was rated as fair or poor in more than one half of the shops visited in Ethiopia [39].8 Trends in Parasitology, Month 2021, Vol. xx, No. xx
Box 3. Diagnostic methods for resistant infections of AAT
Drug resistance can be detected via inoculation and treatment tests in ruminants and mice. In vitro testing has been difficult to
achieve with T. congolense, and adaptation of T. vivax field isolates to culture is not yet possible. Clearly, development of
in vitro systems for cultivating bloodstream forms of both parasiteswill be of significant value. Tests in ruminants occur on infected
animals whereby they are treated with a trypanocide and monitored for cure or treatment failure over 100 days in a laboratory
setting where there is no risk of reinfection. This is costly and labour intensive to perform and does not reflect field settings. Block
treatment studies and longitudinal studies on parasitological data can be done in the field on ruminants. This involves analysing
the number of infections following a block (group) treatment to animals and comparing the number of infections in an untreated
group. The longitudinal data collected can be used to compare incidence and prevalence with varying treatment regimes.
Mice can be similarly infected, with data on the curative dose in a proportion of mice, and a single dose approach has been
developed to enable relatively objective analysis of resistance and diminish the costs of testing [45]. However, this still
requires facilities and expertise to be available, many strains of T. vivax do not grow in mice, and the results in mice do
not always correlate to cattle.
Trypanocidal drug ELISAs in combination with parasite detection can be used together to detect resistant trypanosomes
[59,60]. When trypanosomes are present at specified concentrations of trypanocides, one can deem it a resistant infec-
tion. However, there are issues with variability of pharmacology of trypanocides in cattle that can lead to inaccurate results.
Molecular tests seeking resistance-related genes have not so far been reliably developed for AAT. One test purporting to
detect resistance to DZ, based on different forms of a gene encoding transporter (TcoAT1) [61], does not in fact reveal
resistance. The transporter encoded by the gene does not transport DZ, and any link between different forms was
coincidental [62]. Studies using this test should be disregarded. It is hoped that the identification of genes apparently linked
to ISM resistance [63] might offer routes to genetic tests if validated. Loss of genes encoding CBP1 serine
caboxypeptidase [56] offers a possible route to genetic testing for the benzoxaborole class if they are marketed for use.
Regardless of the diagnostic method used, the cost must be a consideration as it must be accessible to settings in SSA,
and ideally less costly than the treatment for AAT.
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wildlife-protected areas, are often blamed for their inappropriate (administering drug without
diagnosis of causative agent, or incorrect administration) use of livestock medications [21,29].
These farmers are acutely aware of the problems but are systemically excluded from veterinary
care and therefore have no other choice but to make treatment decisions on their own. Farmers,
and those from whom they seek advice, suffer from a lack of knowledge on AAT and often have
low levels of education [22,39]. However, farmers are willing to pay for animal-health services
when they are available and trusted, and imaginative solutions are needed to improve service pro-
visionwithin the existing resource constraints to allow farmers to use trypanocidesmore effectively.
Interventions at local, national, and international levels to improve the effective
use of trypanocides
Whilst several international or large-scale regional AAT-control programmes have been instigated
over the past few decades, most have focused predominantly on tsetse control, with no large-
scale strategies for optimizing the use of trypanocides as part of AAT control. A progressive control
pathway (PCP) has been outlined for AAT [51]. The issue of wildlife reservoirs, and lack of sustainable
methods to eradicate tsetse, renders eradication of AAT an unlikely goal, but a logical and disciplined
framework offers the possibility of incremental progression towards the challenge. Whilst the PCP
acknowledges the role of trypanocides, the later stages (3–5) rely on large-scale control of tsetse.
However, most countries endemic for AAT are in the early stages [7] and livestock keepers are heavily
dependent on trypanocides. Further research and guidance to promote effective and sustainable use
of trypanocides would be beneficial to help inform national and international strategies.
Paired with national and international programmes, community engagement is essential to
mitigate AMR. Methods suggested include enhanced approaches at community-level education,
including better public health messaging via veterinary services, use of radio to reach more ruralTrends in Parasitology, Month 2021, Vol. xx, No. xx 9
Box 4. Improving reporting of control practices of AAT in field studies
Epidemiologic studies on AAT are typically cross-sectional, with farmer-reported results providing data of limited resolution
and value. Another common study type has involved evaluating drug resistance through interventional trials. Interventional
studies evaluating resistance through administration of trypanocides to infected animals to test treatment failure are often
hampered by lack of clarity on whether animals are persistently infected or reinfected, given difficulties in following individ-
ual animals over time within a given study. This makes it unclear if there is genuine resistance or if there is a high risk of
reinfection. These studies also use varying methodologies, and particularly use different diagnostic approaches with
varying sensitivities and specificities, making them difficult to compare. This lack of robust epidemiologic data on AAT
control interventions makes it difficult to implement evidence-based decisions about AAT control.
We suggest three routes to improve consistency and reporting in AAT epidemiology studies:
(i) Standardized reporting methods for epidemiologic studies should be used. In trials, the Consolidated Standards of
Reporting Trials (CONSORT) check list can be used, whereas in observational studies the Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE) check list can be used. Consultation with an
epidemiologist and/or statistician should be considered if one is not already part of the research team.
(ii) When reporting, special attention should be paid to sampling size and strategy, eligibility, refusal rate for participation,
sample size contributing to reported statistics, descriptive data on study participants, measurement of reported data
(farmer or investigator), handling of missing data, study dates, randomization and blinding in interventional studies,
and reporting full statistical models instead of partial ones.
(iii) Standard operating procedures should be developed for common methodologies to improve comparability between
studies. When developing these, attention should be paid to ensuring that protocols are as practical as possible for
field scenarios or areas with limited infrastructure.
Trends in Parasitology
OPEN ACCESSareas, bridging cultural disconnects, and relationship building [21,29]. However, training alone is
found to be ineffective unless it is partnered with incentives, accountability, and a sustainable plan
for local ownership and responsibility [25,26].
Implications of the current use of trypanocides in the field for new drug
development and deployment
The presence of resistance to existing drugs suggests that new drugs will be an essential
pathway to manage AAT; however, counterfeit or poor-quality drugs on the market disincentivize
the legitimate market for currently available and new trypanocides [21]. Work is ongoing to
evaluate combined drug therapy [52], and novel trypanocides [53], with the most promise
shown by the benzoxaborole class [54]. Benzoxaboroles appear to inhibit the trypanosome
CPSF3 protein, involved in mRNA processing [55], a mode of action distinct from other
trypanocides, diminishing the risks of cross-resistance. The leading veterinary class of
benzoxaboroles can accumulate at very high concentrations in the parasite because the parent
compound (e.g., AN11736) is a prodrug that is activated by enzymatic cleavage [56]. However,
T. brucei and T. congolense can lose the genes that encode the prodrug-activating enzyme,
rendering the drug less effective and leading to resistance. Trypanosoma vivax is likely to use
the same mechanism, rendering it equally susceptible to this issue [56].
Trypanocides currently in use were developed during the early postcolonial period. Subsequently,
the merger of international pharmaceutical companies, and increased focus on markets with higher
profit margins, has led to the neglect of the needs of relatively poor farmers in Africa. However, things
are changing. The Global Alliance for Livestock Veterinary Medicines (GALVmed) was founded in
2011 to address failure in the provision of new products for animal health in LMICs, and GALVmed
brought forward the benzoxaborole class, initially discovered by Anacor Pharmaceuticals [57].
Pharmaceutical companies are increasingly involved in initiatives to improve farmers’ access to
animal-health drugsii. It appears, therefore, that after a 50-year hiatus, opportunities to reinvigorate
animal health care in Africa are emerging. However, pharmaceutical companiesmay lack awareness
of consumer demands, needs, and drivers for trypanocide use, and efforts are still needed to bridge




What is the baseline level of AAT and
associated use of trypanocides in field
settings across SSA in all livestock
species?
What quantities of trypanocides are
being used per year across SSA, and
at what cost to the farmer?
What are the sources of trypanocides
being used in SSA, and what is their
quality standard?
What are the true rates of treatment
failure in cases of AAT (due to drug ad-
ministration, handling, and quality) and
trypanocide resistance in different field
settings?
Can low-cost diagnostic methods be
introduced to detect AAT in the field
and diagnose resistant infections?
How can international, national, and
local investment create sustainable
and integrated methods to use
trypanocides and control AAT?
How can behavioural changes in
farmers with limited access to animal-
health services be fostered to allow
sustainable administration of medica-
tions to livestock?Concluding remarks
Farmers are heavily dependent on trypanocides and invest substantial funds to control AAT. New
drug development is an essential component in managing AAT; however, there are serious
problems which need to be addressed regarding current trypanocide use in order for new drugs
to be used effectively in a field setting. At this time, the volume and types of trypanocides being
used across all livestock species, and at what cost, is unclear. The sources of these medications,
and their quality, also remain mired with concerns of quality and counterfeiting. Publications on
trypanocide resistance lack comparability and clarity on instances of resistance vs. reinfection, or
treatment failure due to other issues around drug administration. There are no publications that
the authors could find on the rate of treatment failure using accurate diagnostic tests with
farmer-administered medications. Research on AAT needs to meet higher epidemiological quality
standards through the use of more standardized protocols, as well as the use of CONSORT,
STROBE (Box 4), or similar checklists to ensure that data are of high quality and comparable.
Farmer education, lack of affordable and easy-to-use diagnostics for AAT, and inappropriate use of
trypanocides must all be addressed to ensure that both current and new drugs can be used
appropriately in the control of AAT. Control programmes need to be sustainable at the local,
national, and international level, and must be standardized. Funding is a key component once
there is cross-sectoral commitment to these programmes, but major behavioural change is
required. These all remain challenges as there is no clear leader or success story to emulate or
learn lessons from (see Outstanding questions).
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